Eloctate FDA Approval History
FDA Approved: Yes (First approved June 6, 2014)
Brand name: Eloctate
Generic name: antihemophilic factor (recombinant)
Dosage form: for Injection
Company: Biogen Inc.
Treatment for: Hemophilia A
Eloctate (antihemophilic factor (recombinant) Fc Fusion Protein is a recombinant DNA derived, antihemophilic factor indicated for the treatment of patients with Hemophilia A.
Development timeline for Eloctate
| Date | Article |
|---|---|
| Jun 6, 2014 | Approval FDA Approves Eloctate - first Antihemophilic Factor, Fc Fusion Protein for Patients with Hemophilia A |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
